Navigation Links
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/17/2008

future treatment regimens. Audience participation and Q&A are encouraged.

Schering-Plough Satellite Symposium at EASL

From Initial Therapy to a Second Chance: A Comprehensive Guide to HCV Treatment

Sunday, April 27, 8:30-10:00 a.m., Milan Convention Center, Hall B.

A world-renowned faculty will present and discuss emerging data that answer several of the most relevant questions in HCV treatment today and for the future: the most effective use of peginterferon in combination with ribavirin in initial therapy, the optimal approach to the retreatment of patients with chronic HCV for whom initial treatment was not effective, and the outlook for HCV treatment in the future. Following the scientific presentations, the faculty will engage in a panel discussion based on questions posed by the symposium attendees, providing an opportunity for dialogue around the most urgent issues facing HCV-treating clinicians today.

About Hepatitis C

Hepatitis C is a serious and potentially life-threatening disease. It is the most common blood-borne infection in America and Europe, and the most common form of liver disease, affecting nearly 5 million people in the United States, 5 million in Europe and some 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States and Europe.

About PEGINTRON

In the United States, PEGINTRON is indicated for use alone or with ribavirin for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and who are at least 18 years of age.

Important Safety Information Regarding U.S. Labeling for PEGINTRON and REBETOL

Alpha interferons, including PEGINTRON and INTRON(R) A, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
2. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
3. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
4. Schering-Plough Reports Top-Line Results of the IDEAL Study
5. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
6. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
7. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
8. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
10. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
11. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014   LabStyle Innovations Corp . ... announced the appointment of Professor Richard B. ... Board of Directors. Prof. Stone brings ... to LabStyle as an entrepreneur, venture capitalist public, ... governance expert. He currently serves on the board ...
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
(Date:7/11/2014)... 2014 Riverside Health System became the first ... Virginia in late 2012 and now, in partnership with Williamsburg ... throughout the Williamsburg and Newport News region. , Also known ... benefits to independent older adults who wish to remain in ... net of continuing care services as well as control over ...
(Date:7/11/2014)... scientists have been trying to unravel mechanisms that guide ... that generate all blood cells including our immune system. ... because they can only be found in the bone ... a culture dish. Now a group of scientists from ... (Technische Universitt Dresden) was able to generate a mouse ...
(Date:7/11/2014)... Salt Lake City, UT (PRWEB) July 11, 2014 ... hard at work at the Kilimanjaro Kids Community in Tanzania. ... children, 40 goats, 150 chickens, and two cows. HOP Founder, ... and provide education for some of the orphaned children he ... week, the HOP Team visited the children, who have all ...
(Date:7/11/2014)... San Francisco shows that an "expressive therapy" group ... living with HIV disclose their health status and ... and quality of their relationships., "Medication alone is ... L. Machtinger, MD, director of the Women,s HIV ... patients are on effective antiretroviral therapy but far ...
(Date:7/11/2014)... July 11, 2014 Recently, iFitDress.com, a ... occasion outfits, has released its new collection of ... the company has announced that all these beautiful items ... The deadline of the special offer is July 22. ... major officials pay close attention to customer satisfaction. On ...
Breaking Medicine News(10 mins):Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4Health News:Opening-up the stem cell niche 2Health News:Human Outreach Project Sees Incredible Progress in the Kilimanjaro Kids Community 2Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Worldwide Chic Ladies Can Buy Cheap Evening Dresses at iFitDress.com 2
... challenges in managing their blood glucose levels, and it ... system providing continuous real-time glucose readings. Today, The Endocrine ... on settings where patients are most likely to benefit ... way to self-check blood glucose levels is to prick ...
... caught in its early stages, prostate cancer is treatable ... threshold, the disease becomes largely resistant to current treatments. ... of cancer biologists $9.55 million over five years to ... progresses to the therapy-resistant state. The Program Project ...
... Netherlands, 11 October 2011 Alzheimer,s disease (AD) is ... the world. A new supplement to the ... clearly shows that multiple imaging systems are now available ... "Alzheimer,s disease is now seen as a ...
... published in the October issue of the Journal of ... breast malignancies accounting for 0.5 to one percent of all ... patients. Population-based estimates indicate that the incidence of malignant phyllodes ... frequencies in Hispanic women. Previous studies have focused on ...
... the start of 2011, the active ingredient ticagrelor can ... (ASA) to avoid blood clots in patients with acute ... Quality and Efficiency in Health Care (IQWiG) has now ... coronary syndrome (ACS) in comparison with conventional drugs. This ...
... team of researchers, Gloria Petersen, Ph.D. , of ... California, San Francisco, and Susan Wolf, J.D., of the University ... the National Cancer Institute and the National Human Genome Research ... genetic research results, such as DNA test results, from tissue ...
Cached Medicine News:Health News:Experts find continuous glucose monitoring beneficial in maintaining target blood glucose levels 2Health News:$9.55 million NCI grant targets the resistance of advanced prostate cancer 2Health News:Advances in brain imaging can expedite research and diagnosis in Alzheimer's disease 2Health News:Advances in brain imaging can expedite research and diagnosis in Alzheimer's disease 3Health News:Hispanic women have higher incidence of rare breast tumor 2Health News:Ticagrelor: Considerable added benefit for specific patients 2Health News:Ticagrelor: Considerable added benefit for specific patients 3Health News:Ticagrelor: Considerable added benefit for specific patients 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: